BCL2 and small cell lung carcinoma: In all, our experimental data suggest that targeting the HOTTIP–BCL-2 interaction may represent a novel therapeutic application, thus contributing a better knowledge to choose the combination therapy based on chemotherapy and combining with biological therapy for BCL-2 positive SCLC patients.